Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Cash & Equivalents (2016 - 2025)

Seres Therapeutics' Cash & Equivalents history spans 11 years, with the latest figure at $47.6 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 28.71% year-over-year to $47.6 million; the TTM value through Sep 2025 reached $47.6 million, down 28.71%, while the annual FY2024 figure was $30.8 million, 75.94% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $47.6 million at Seres Therapeutics, up from $45.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $272.5 million in Q1 2021 and bottomed at $30.8 million in Q4 2024.
  • The 5-year median for Cash & Equivalents is $128.0 million (2023), against an average of $137.9 million.
  • The largest annual shift saw Cash & Equivalents skyrocketed 396.84% in 2021 before it crashed 75.94% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $180.0 million in 2021, then dropped by 9.43% to $163.0 million in 2022, then dropped by 21.51% to $128.0 million in 2023, then crashed by 75.94% to $30.8 million in 2024, then skyrocketed by 54.7% to $47.6 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Cash & Equivalents are $47.6 million (Q3 2025), $45.4 million (Q2 2025), and $58.8 million (Q1 2025).